Compare Boston Scientific Corporation (BSX) vs Keysight Technologies Inc (KEYS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Keysight Technologies Inc — how do they compare? Boston Scientific Corporation trades at $42.87 (market cap $66.37B), while Keysight Technologies Inc trades at $323.32 (market cap $55.67B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | KEYS | |
|---|---|---|
Market Cap | $66.37B | $55.67B |
Sector | Health | Technology |
52-Week High | $108.14 | $373.34 |
52-Week Low | $42.63 | $158.51 |
Enterprise Value | $75.94B | $56.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Keysight Technologies (KEYS) trades at $320.83, down 0.38% today, with technical indicators showing a bearish trend near key support at $317. The company reported strong Q1 2026 earnings of $2.87 per share, beating estimates of $2.32, and maintains robust profitability with a 17.31% net income margin. Recent news highlights product launches in network cybersecurity and photonics design, supporting growth in AI and 5G markets.
Wall Street maintains a bullish outlook with a $396.56 consensus price target and 75% buy ratings, though high valuation multiples and volatile cash flows pose risks. Upside potential hinges on execution in high-growth tech sectors, while investor sentiment is tempered by near-term technical weakness and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →
